Last reviewed · How we verify
Prevention of Transient Ischemic Attacks — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Crestor | rosuvastatin | AstraZeneca | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase | 2003-01-01 | |
| Zocor | simvastatin | Merck & Co. | HMG-CoA Reductase Inhibitor [EPC] | Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AstraZeneca · 1 drug in Prevention of Transient Ischemic Attacks
- Merck & Co. · 1 drug in Prevention of Transient Ischemic Attacks
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of Transient Ischemic Attacks:
- Prevention of Transient Ischemic Attacks treatment updates — RSS
- Prevention of Transient Ischemic Attacks treatment updates — Atom
- Prevention of Transient Ischemic Attacks treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of Transient Ischemic Attacks — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-transient-ischemic-attacks. Accessed 2026-06-11.
Related
- Prevention of Transient Ischemic Attacks full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing